A

Alnylam Pharmaceuticals Tech Stack

RNAi therapeutics company with approved medicines and clinical pipeline

Biotechnology Research Cambridge, Massachusetts 1,001–5,000 employees Founded 2002 Public Company

Alnylam develops RNA interference therapeutics—a platform for silencing disease-causing genes. The company operates a distributed research and regulatory machine: six approved medicines in market, active bench-to-bedside clinical programs, and hiring velocity concentrated in research (54 open roles), healthcare (30), and regulatory functions (directors and specialists dominating the seniority mix). Pain points cluster around compliance, regulatory submission timelines, and field sales process maturity, signaling a scaling organization balancing rapid clinical advancement with operational rigor.

Tech Stack 77 technologies

Core StackSAS MATLAB Salesforce Jira Confluence SAP Zoom Veeva PromoMats R CDISC HPLC LC-MS MES ERP qPCR NONMEM Phoenix WinNonlin Veeva Excel PowerPoint Word Ironclad Windows RT-qPCR GraphPad Prism SharePoint Adobe Acrobat SAP ERP Microsoft Office Outlook+44 more

AdoptingR Shiny

What Alnylam Pharmaceuticals Is Building

◆Challenges

Ensuring compliance with gcp
Timely regulatory submissions
Vendor compliance oversight
Inspection readiness
Budget constraints
Improving field sales processes
Country challenges impacting study delivery
Process inefficiencies
Budget oversight
Risk reviews

▲Active Projects

Bench-to-bedside early phase clinical development programs
Risk management plan development
Medical education initiatives
Real world evidence generation
Development and implementation of regulatory operational systems
Advisory boards, symposia and publication planning
Process and procedure development for compliance and quality metrics
Tmf archiving
Regulatory submission support
Inspection readiness support

Hiring Activity

Accelerating230 roles · 100 in 30d

Department

Research

54

Healthcare

30

Sales

21

Ops

20

Data

17

Legal

17

Manufacturing

12

Operations

10

Seniority

Director

100

Senior

71

Manager

22

Principal

14

Mid

13

VP

4

Junior

3

Lead

2

Notable leadership hires: Biostatistics Director, Director Manufacturing, Regulatory Lead, Medical Director, Head of Search & Evaluation

Company intelligence

Find more companies like Alnylam Pharmaceuticals by tech stack, pain points and active projects

Get started free

About Alnylam Pharmaceuticals

Alnylam is an independent biopharmaceutical company pioneering RNA interference therapeutics. Founded in 2002, the company has commercialized six RNAi-based medicines and maintains a pipeline addressing rare and prevalent diseases. Operations span research, clinical development, regulatory affairs, manufacturing, and commercial sales across North America, Europe, Asia, and South America. The organization employs 2,600+ people and is structured around core functions: bench research, clinical program execution, regulatory operations, manufacturing, and field sales. Tech infrastructure reflects pharmaceutical development workflows: Veeva (regulatory and promotional materials), SAS and R (biostatistics), Salesforce (commercial CRM), and enterprise systems (SAP ERP, SharePoint).

HeadquartersCambridge, Massachusetts

Company Size1,001–5,000 employees

Founded2002

Hiring MarketsSwitzerland, United States, United Kingdom, Germany, Belgium, Brazil, Italy, Netherlands

Frequently Asked Questions

What is Alnylam Pharmaceuticals working on?

Six approved RNAi therapeutics in market. Active programs: early-phase clinical development bench-to-bedside, real-world evidence generation, risk management planning, regulatory submission support, inspection readiness, and medical education initiatives targeting both rare and prevalent diseases.

What countries does Alnylam hire in?

United States, Switzerland, United Kingdom, Germany, Belgium, Brazil, Italy, Netherlands, France, and Canada—reflecting global clinical trial and manufacturing operations.